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RESEARCH
Predicting outcome after traumatic brain injury: practical
prognostic models based on large cohort of international
patients
MRC CRASH Trial Collaborators
ABSTRACT
Objective To develop and validate practical prognostic
models for death at 14 days and for death or severe
disability six months after traumatic brain injury.
DesignMultivariable logistic regression to select
variables that were independently associated with two
patient outcomes. Two models designed: “basic”model
(demographic and clinical variables only) and “CT” model
(basic model plus results of computed tomography). The
models were subsequently developed for high and low-
middle income countries separately.
SettingMedical Research Council (MRC) CRASH Trial.
Subjects 10008 patients with traumatic brain injury.
Models externally validated in a cohort of 8509.
Results The basic model included four predictors: age,
Glasgow coma scale, pupil reactivity, and the presence of
major extracranial injury. The CT model also included the
presence of petechial haemorrhages, obliteration of the
third ventricle or basal cisterns, subarachnoid bleeding,
midline shift, and non-evacuated haematoma. In the
derivation sample the models showed excellent
discrimination (C statistic above 0.80). The models
showed good calibration graphically. The Hosmer-
Lemeshow test also indicated good calibration, except for
the CT model in low-middle income countries. External
validation for unfavourable outcome at six months in high
income countries showed that basic and CT models had
good discrimination (C statistic 0.77 for both models) but
poorer calibration.
Conclusion Simple prognostic models can be used to
obtain valid predictions of relevant outcomes in patients
with traumatic brain injury.
INTRODUCTION
Traumatic brain injury is a leading cause of death and
disability worldwide. Every year, about 1.5 million
affected people die and several millions receive
emergency treatment.1 2 Most of the burden (90%) is
in low and middle income countries.3
Clinicians treating patients often make therapeutic
decisions based on their assessment of prognosis.
According to a 2005 survey, 80% of doctors believed
that an accurate assessment of prognosiswas important
when they made decisions about the use of specific
methods of treatment such as hyperventilation, barbi-
turates, or mannitol.4 A similar proportion considered
that this was important in deciding whether or not to
withdraw treatment. Assessment of prognosis was also
deemed important for counselling patients and rela-
tives. Only a third of doctors, however, thought that
they accurately assessed prognosis.4
Prognostic models are statistical models that com-
bine data from patients to predict outcome and are
likely to be more accurate than simple clinical
predictions.5 The use of computer based prediction of
outcome in patients with traumatic brain injury
increases the use of certain therapeutic interventions
in those predicted to have a good outcome and reduces
their use in those predicted to have a poor outcome.6
Many prognostic models have been reported but
none arewidely used.A recent systematic reviewoffers
possible explanations.7 Most models were developed
on small samples, most weremethodologically flawed,
and few were validated in external populations. Few
were presented in a clinically practical way, nor were
they developed in populations from low and middle
income countries, where most trauma occurs.
The Medical Research Council (MRC) CRASH
(corticosteroid randomisation after significant head
injury) trial is the largest clinical trial conducted in
patients with traumatic brain injury and presents a
unique opportunity to develop a prognostic model.8 9
The trial prospectively included patients within eight
hours of the injury, used standardised definitions of
variables, and achieved almost complete follow-up at
six months. Furthermore, the large sample size
guarantees precise and valid predictions. The high
recruitment of patients from low and middle income
countriesmeans thatmodels developedwith these data
are relevant to these settings.
We have developed and validated prognostic
models for death at 14 days and death and disability
at six months in patients with traumatic brain injury.
METHODS
Patients—The study cohort was all 10 008 patients
enrolled in the trial. Adults with traumatic brain injury,
who had a score on the Glasgow coma scale of 14 or
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less, and who were within eight hours of injury, were
eligible for inclusion in the trial.
Outcomes—Death of a patient was recorded on an
early outcome form that was completed at hospital
discharge, death, or 14 days after randomisation
(whichever occurred first). Unfavourable outcome
(death or severe disability) at six months was defined
with the Glasgow outcome scale (see box). The scale
comprises five categories: death, vegetative state,
severe disability, moderate disability, and good recov-
ery. For the purpose of this analysis, we dichotomised
outcomes into favourable (moderate disability or good
recovery) and unfavourable (dead, vegetative state, or
severe disability).10
Prognostic variables—For the prognostic model we
considered age, sex, cause of injury, time from injury to
randomisation, Glasgow coma score at randomisation,
pupil reactivity, results of computed tomography,
whether the patient had sustained a major extracranial
injury, and level of income in country (high or low-
middle income countries, as defined by the World
Bank) (see tableAonbmj.com).11Weadjustedanalyses
for treatment within the trial as this was related to
outcome, and we did not find interaction between
treatment and the potential predictors.8 9
Analysis—Most of the variables collected in the
CRASH trial have been previously associated with
prognosis in traumatic brain injury, so we included all
of them in a first multivariable logistic regression
analysis.12 We excluded variables that were not
significant at 5% level. We quantified each variable’s
predictive contribution by its z score (the model
coefficient divided by its standard error).We explored
linearity between age and mortality at 14 days and
Glasgow coma score and mortality at 14 days. Inter-
actions between country income level and all the other
predictors were evaluated with a likelihood ratio test.
Because there were few data missing, we performed a
complete case analysis.
Prognostic models—We developed different models
for each of the two outcomes: a basic model, which
included only clinical and demographic variables, and
a CT model, which also included results of computed
tomography.
Performance of themodel—Weassessedperformanceof
the models in terms of calibration and discrimination.
Calibration was assessed graphically and with the
Hosmer-Lemeshow test. Discrimination was assessed
with theC statistic (an equivalent concept to area under
the receiver operator characteristic curve).13
Internal validation—The internal validity of the final
model was assessed by the bootstrap re-sampling
technique. Regression models were estimated in 100
models. For each of 100 bootstrap samples we refitted
and tested the model on the original sample to obtain
an estimate of predictive accuracy corrected for bias.
This showed no overoptimism in any of the final
model’s predictive C statistics.
External validation—A good prognostic model
should be generalisable to populations different to
those inwhich itwasderived.14Weexternallyvalidated
the models in an external cohort of 8509 patients with
moderate and severe traumatic brain injury from 11
studies conducted in high income countries (the
IMPACT (international mission for prognosis and
clinical trial) dataset).15
Score development—We developed a clinical score
based on regression coefficients. A web based version
of the model was developed to be accessible to
clinicians internationally.
Category and definition onGlasgowoutcome scale
 Good recovery: able to return to work or school
 Moderate disability: able to live independently; unable to return to work or school
 Severe disability: able to follow commands/unable to live independently
 Persistent vegetative state: unable to interact with environment; unresponsive
 Dead
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RESULTS
General characteristics
Table 1 shows the characteristics of the patients. More
of the patients were men (81%) and more came from
low-middle income countries (75%). More than half
(58%) of participants were included within three hours
of injury. Road traffic crashes were the most common
cause of injury (65%) and 79% of the participants
underwent computed tomography. A total of 1948
patients (19%) died in the first twoweeks, 2323 patients
(24%)weredead at sixmonths, and3556patients (37%)
were dead or severely dependent at six months.
The relation between age and the log odds of death
within14days showednoassociationuntil the ageof 40
and a linear increase afterwards. The relation between
Glasgow coma score and mortality at 14 days was
reasonably linear and we therefore included the coma
score as a continuous variable (figs 1 and 2). The
relation with unfavourable outcome at six months
showed similar patterns.
Low-middle v high income countries
In comparison with patients from high income
countries, those from low-middle income countries
were younger, more likely to be male, were recruited
later, had less severe traumatic brain injury (as defined
byGlasgowcoma score andpupil reactivity), andmore
often had abnormal results on computed tomography.
Road traffic crashes were a more common cause of
traumatic brain injury. Although patients from low-
middle income countries experiencedhighermortality
at 14 days (odds ratio 1.94, 95% confidence interval
1.64 to 2.30), there was no significant difference in
unfavourable outcome at six months.
There were significant interactions between the
country’s income level and several predictors and so
we developed twomodels, one for low-middle income
countries andanother forhigh incomecountries.Older
agewas a stronger predictor of 14 daymortality in high
income countries (interaction P<0.001), and lower
Glasgow coma score was a stronger predictor in low-
middle income countries (interaction P=0.003). Oblit-
eration of the third ventricle and a non-evacuated
haematoma were both associated with a higher risk in
high income countries (interaction P<0.001 and
P=0.03, respectively).
Multivariable predictive models
We developed eight models altogether: basic and CT
models for predicting two outcomes in two settings
(low-middle and high income countries).
Basic models—We included four predictors in the
basicmodel: age,Glasgowcomascore,pupil reactivity,
and the presence ofmajor extracranial injury (table 2).
Glasgow coma score was the strongest predictor of
outcome in low-middle income countries and age was
the strongest predictor in high income countries, while
the absence of pupil reactivity was the third strongest
predictor in both regions.
CT models—The following characteristics on com-
puted tomography were strongly associated with the
outcomes in addition to the predictors included in the
basic models: presence of petechial haemorrhages,
obliteration of the third ventricle or basal cisterns,
subarachnoid bleeding, midline shift, and non-evac-
uated haematoma (table 3). Obliteration of the third
ventricle and midline shift were the strongest
Table 1 | General characteristics of study population
Total (n=10
008)
Low-middle
income
countries (n=7
526)
High income
countries (n=2
482) P value*
Age (years):
<20 12.3 12.5 11.8
20-24 17.0 17.8 14.4
25-29 13.0 13.5 11.2
30-34 10.7 10.9 10.1
35-44 17.9 18.5 15.9
45-54 12.5 12.3 13.3
≥55 16.7 14.5 23.4
Mean (SD) 37 (17.1) 35.8 (16) 40.6 (19.4) <0.001
Sex:
Female 19.0 18.3 21.1
0.002
Male 81.0 81.7 78.9
Hours since injury :
<1 26.8 24.0 35.2
1-3 31.0 30.1 33.7
>3 42.3 45.9 31.1
Mean (SD) 3.4 (2.7) 3.6 (2.8) 2.8 (2.0) <0.001
Cause of head injury:
Road traffic crash 65.1 69.9 50.2
<0.001Fall >2 meters 13.3 11.1 20.0
Other 21.7 19.0 29.8
Total Glasgow coma score:
Mild (13-14) 30.2 29.4 32.6
<0.001Moderate (9-12) 30.4 32.6 23.6
Severe (3-8) 39.5 38.0 43.8
Pupil reactivity:
Both reactive 82.8 83.5 80.7
<0.001
One reactive 6.3 6.2 6.3
None reactive 8.2 8.0 9.1
Unable to assess 2.7 2.3 3.9
Major extracranial injury:
No 77.3 77.3 77.5
0.801
Yes 22.7 22.7 22.5
Computed tomography:
No scan 21.1 24.0 12.0 <0.001
Normal scan 22.8 20.0 30.2 <0.001
Petechial haemorrhages 28.7 28.7 28.7 0.970
Obliteration of 3rd ventricle
or basal cisterns
23.4 28.6 9.6 <0.001
Subarachnoid bleed 31.6 33.5 26.4 <0.001
Midline shift 14.6 15.9 11.1 <0.001
Non-evacuated haematoma 27.1 27.3 26.5 0.475
Evacuated haematoma 12.7 14.4 7.9 <0.001
Outcomes:
Mortality at 14 days 19.5 20.7 16.0 <0.001
Death or severe disability at
6 months
37.2 36.8 38.5 0.150
*P value for comparison between low-middle income countries and high income countries.
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predictors of mortality at 14 days, and non-evacuated
haematoma was the strongest predictor of unfavour-
able outcome at six months.
Performance of models—All models showed excellent
discrimination, withC statistics over 0.80 (tables 2 and
3).Calibration in allmodelswas adequate and sixout of
the eight models had good calibration when evaluated
with the Hosmer-Lemeshow test (figs 3 and 4).
Clinical score—Individual scores and their respective
probability of outcome can be obtained from our web
based calculator (www.crash2.lshtm.ac.uk/). By enter-
ing the values of the predictors, we can obtain the
expected risk of death at 14 days and of death or severe
disability at six months. Figure 5 shows a sample
screenshot of the predictions for a 26 year old patient
from a low and middle income country (Argentina),
with a Glasgow coma score of 11, one pupil reactive,
and absence of a major extra cranial injury. According
to thebasicmodel this patient has a probability of death
at 14 days of 10% and a 23.9% risk of death or severe
disability at six months. A good agreement is evident
between observed and predicted outcome by the web
calculator (figs 3 and 4).
External validation—Because an external cohort of
patients from low-middle income countries was not
available, we validated the models in patients from
high income countries only. The IMPACT dataset
used for the validation did not include mortality at
14 days and so we could validate only models for
unfavourable outcome at sixmonths.We validated the
basic model with the variables age, Glasgow coma
score, and pupil reactivity. We did not include the
variable “major extracranial injury” as it was not
available in the validation sample. For the CTmodels,
we added obliteration of the third ventricle or basal
cisterns, subarachnoid bleeding, midline shift, and
non-evacuated haematoma to the basic model. Simi-
larly, we excluded the variable “petechial haemor-
rhages” as this was not available in the validation
Table 2 | Multivariable basic predictivemodels (excluding data fromcomputed tomography*). Figures are odds ratios (95%
confidence intervals)with z scores
Prognostic variables
Mortality at 14 days Death or severe disability at 6 months
High income countries
(n=2294)
Low-middle income
countries (n=7412)
High income countries
(n=2185)
Low-middle income
countries (n=7119)
Age† 1.72 (1.62 to 1.83),
14.08
1.47 (1.40 to 1.54),
14.10
1.73 (1.64 to 1.82),
15.99
1.70 (1.63 to 1.77),
18.58
GCS‡ 1.24 (1.19 to 1.29),
10.22
1.39 (1.35 to 1.42),
25.60
1.22 (1.18 to 1.25),
12.84
1.42 (1.39 to 1.45),
30.64
Pupil reactivity:
Both 1 1 1 1.00
One 2.57 (1.65 to4.00), 4.17 1.91 (1.53 to 2.39), 5.69 2.43 (1.62 to3.66), 4.26 2.01 (1.59 to 2.56),
5.81
None 5.49 (3.70 to8.15), 8.45 3.92 (3.14 to 4.90),
12.07
3.28 (2.20 to4.89), 5.85 4.54 (3.38 to 6.11),
10.03
Major extracranial injury:
No 1 1 1 1.00
Yes 1.53 (1.11 to2.09), 2.62 1.15 (0.99 to 1.34), 1.78 1.62 (1.26 to2.07), 3.82 1.73 (1.51 to 1.99),
7.76
C statistic 0.86 0.84 0.81 0.84
GCS=Glasgow coma scale.
*Includes age, GCS, sex, hours since injury, cause of injury, pupil reactivity, and presence of major extracranial injury.
†Per 10 year increase after 40 years.
‡Per decrease of each value of GCS.
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RESEARCH
page 4 of 10 BMJ | ONLINE FIRST | bmj.com
sample. For the validation process we first ran these
models in theCRASH trial cohort andwe then applied
the correspondingcoefficients in thevalidation sample.
Although discrimination was, as expected, lower than
in the original data, it was still quite good for both the
basic andCTmodels (C statistic 0.77 for bothmodels).
The calibration was excellent for the CT model but
poorer for the basic model (figs 6 and 7).
DISCUSSION
We have developed web based prognostic models for
predicting two clinically relevant outcomes in patients
with traumatic brain injury using variables that are
available at the bedside. The models have excellent
discrimination and good fit with both internal and
external validation.Wehave reportedondifferences in
outcomes and on the strength of predictors of out-
comes, according to whether patients are from high or
low-middle income countries.
Older age, low Glasgow coma score, absent pupil
reactivity, and the presence of major extracranial
injury predict poor prognosis. All of these variables
have been previously identified as prognostic factors
for poor outcome in traumatic brain injury.12 Glasgow
coma score showed a clear linear relation with
mortality. Our finding that mortality in patients with
Glasgow coma score of 3 was lower than in patients
with a score of 4 may be because scores of sedated
patients are reported as 3. Increasing age was
associated with worse outcomes but this association
was apparent only after age 40. A similar threshold has
beenreportedelsewhere.16 17 Plausibleexplanations for
this include extracranial comorbidities, changes in
brain plasticity, or differences in clinical management
associated with increasing age. The presence of
“obliteration of third ventricle or basal cisterns” on
Table 3 | Multivariable predictivemodelswith computed tomography*. Figures are odds ratios (95%confidence intervals)with z scores
Prognostic variables
Mortality at 14 days Death or severe disability at 6 months
High incomecountries (n=2030)
Low-middle income
countries (n=5635) High incomecountries (n=1955)
Low-middle income countries
(n=5 394)
Age† 1.73 (1.62 to 1.84), 13.33 1.46 (1.39 to 1.54), 12.54 1.73 (1.63 to 1.83), 14.94 1.72 (1.64 to 1.81), 17.74
GCS‡ 1.18 (1.12 to 1.23), 6.87 1.27 (1.24 to 1.31), 16.68 1.18 (1.14 to 1.22), 9.83 1.34 (1.30 to 1.37), 22.32
Pupil reactivity:
Both 1 1 1 1.00
One 2.00 (1.25 to 3.20), 2.88 1.45 (1.14 to 1.86), 2.97 2.12 (1.39 to 3.24), 3.47 1.54 (1.20 to 1.99), 3.35
None 4.00 (2.58 to 6.20), 6.21 3.12 (2.46 to 3.97), 9.31 2.83 (1.84 to 4.35), 4.73 3.56 (2.60 to 4.87), 7.92
Major extracranial injury:
No 1 1 1 1.00
Yes 1.53 (1.10 to 2.13), 2.53 1.08 (0.91 to 1.28), 0.89 1.55 (1.20 to 1.99), 3.37 1.61 (1.38 to 1.88), 6.03
Findings on computed tomography:
Petechial haemorrhages 1.15 (0.83 to 1.59), 0.84 1.26 (1.07 to 1.47), 2.82 1.21 (0.95 to 1.55), 1.56 1.49 (1.29 to 1.73), 5.33
Obliteration of 3rd ventricle or
basal cisterns
4.46 (2.97 to 6.68), 7.23 1.99 (1.69 to 2.35), 8.25 2.21 (1.49 to 3.30), 3.95 1.53 (1.31 to 1.79), 5.30
Subarachnoid bleed 1.48 (1.09 to 2.02), 2.51 1.33 (1.14 to 1.55), 3.60 1.62 (1.26 to 2.08), 3.79 1.20 (1.04 to 1.39), 2.49
Midline shift 2.77 (1.82 to 4.21), 4.77 1.78 (1.44 to 2.21), 5.35 1.93 (1.30 to 2.87), 3.24 1.86 (1.48 to 2.32), 5.42
Non-evacuated haematoma 2.06 (1.49 to 2.84), 4.40 1.48 (1.24 to 1.76), 4.43 1.72 (1.33 to 2.22), 4.15 1.68 (1.43 to 1.97), 6.34
C statistic 0.88 0.84 0.83 0.84
GCS=Glasgow coma scale.
*Includes age, GCS, pupil reactivity, presence of major extra cranial injury, and all findings on computed tomography.
†Per 10 year increase after 40 years.
‡Per decrease of each value of GCS.
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computed tomography was associated with the worst
prognosis at 14 days. This is supported by recent
findings that absence of basal cisterns is the strongest
predictor of six month mortality.18 We also found—as
previously reported—the independent prognostic
value of traumatic subarachnoid haemorrhage.19
Patients from low-middle income countries had
worse early prognosis than those from high income
countries. Regional differences in outcome after
traumatic brain injury have previously been reported
betweenEuropeandNorthAmerica, but thedifference
in mortality between low-middle and high income
countries has not been explored.20
The strength of association between some predictors
and outcomes differed by region.A lowGlasgow coma
score had an even worse prognosis in patients from
low-middle income countries compared with patients
from high income countries. This might relate to
quality of care or it could be that low Glasgow coma
score in high income countries is associated with
greater use of sedation, rather than to severity of
traumatic brain injury. Increasing age had a worse
prognosis in high income countries compared with
low-middle income countries. This is because of even
lower risks at younger ages in high income countries,
while both have similar risks at older ages. Regarding
computed tomography, some abnormal findings were
stronger predictors in high income countries. This
could be because of better technology and therefore
more accurate diagnosis with computed tomography.
A systematic review identified over 100 prognostic
models for patients with traumatic brain injury, but
methodological qualitywas adequate in only a few.7As
with our models, two of the more methodologically
robust models showed similarly good discrimination
but worse calibration.17 21 They too included Glasgow
coma score, age, pupil reactivity, and results of
computed tomography as predictors, but, unlike our
models, they did not include the presence of major
extracranial injury, and none of them included patients
from low-middle income countries.
Strengths and weakness of the study
Our study’s strengths are the use of a well described
cohort of patients, prospective and standardised
collection of data on prognostic factors, low loss to
follow-up, and the use of a validated outcomemeasure
at a fixed time after the injury. All of these factors
provide reassurance about the internal validity of our
models.The large sample size in relation to thenumber
of prognostic variables examined is another particular
strength. In relation to its external validity, only a few
prognostic models have been developed from patients
in low-middle income countries, and to the best of our
knowledge themodelswe developed are the first with a
large sample size and adequatemethods.7 The external
validation confirmed the discriminatory ability of the
models in patients from high income countries and
showed good calibration for the computed tomogra-
phymodel. Unlike most published prognostic models,
Fig 5 | Screenshot of web based calculator available at www.crash2.lshtm.ac.uk/. If CT scan
available box is ticked, calculator displays additional CT variables
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we included the complete spectrum of patients with
traumatic brain injury, ranging from mild to severe.
Finally, the data required to make predictions with the
model are easily available to clinicians, and we have
developed a web based risk calculator.
There are some limitations. The data fromwhich the
models were developed come from a clinical trial and
this could therefore limit external validity. For
example, patients were recruited within eight hours
of injury and we cannot estimate the accuracy of the
models for patients evaluated beyond this time.
Nevertheless, the CRASH trial was a pragmatic trial
that did not require any additional tests and therefore
included a diversity of “real life” patients. Another
limitation was that for the validation we were forced to
exclude the variables major extracranial injury and
petechial haemorrhages because they were not avail-
able in the IMPACTsample.Neitherof thesevariables,
however, was among the stronger predictors. The
external validation showed good discriminatory abil-
ity, but this was somewhat lower than in the original
data. This may be explained by a more homogeneous
selected case mix in these other trials, which included
only patients withmoderate and severeGlasgow coma
score.
Implications of the study
Most of the burden of traumatic brain injury is in low-
middle income countries, where case fatality is higher
and resources are limited. We found that several
predictors differed in their strength of association with
outcome according to income level of country,
suggesting that it may be inappropriate to extrapolate
from models for high income countries to poorer
settings.We have developed amethodologically valid,
simple, and accurate model that may help decisions
about health care for individual patients. It is important
to emphasise, however, that while prognostic models
may complement clinical decisionmaking they cannot
and should not replace clinical judgment. This is
particularly important in the context of judgments
about the withdrawal of care or clinical triage. These
prognostic models can also help in the design and
analysis of clinical trials, through prognostic stratifica-
tion, and can be used in clinical audit by allowing
adjustment for case mix.22
Future research
The differences found between the prognostic models
for low-middle and high income countries are impor-
tant. Although most of the burden of trauma occurs in
low-middle income countries, most research takes
place in high income countries.3 A recent systematic
review found that few prognostic models for traumatic
brain injury were developed in low-middle income
countries.7More research is therefore needed to obtain
reliable data from these settings. An improved under-
standingof thedifferencesbetween these regionsmight
also clarify the mechanisms of predictors that are not
immediately obviouswhenweanalyse ahomogeneous
population. Because our models were developed with
data from a clinical trial, and validated only in patients
from high income countries, further prospective
validation in independent cohorts is needed to
strengthen the generalisability of the models. Future
research could also evaluate different ways, or formats,
for presenting the models to physicians; their use in
clinical practice; andwhether ultimately they have any
Probability according to model
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Fig 7 |External validation of CT model for death or severe
disability at six months in IMPACT database
WHAT IS ALREADY KNOWN ON THIS TOPIC
Traumatic brain injury is a leading cause of death and
disability worldwide with most cases occurring in low-
middle income countries
Prognosticmodelsmay improve predictions of outcomeand
help in clinical research
Many prognostic models have been published but
methodological quality is generally poor, sample sizes
small, and only a few models have included patients from
low-middle income countries
WHAT THIS STUDY ADDS
In a basic model prognostic indicators included age,
Glasgow coma scale, pupil reactivity, and the presence of
major extracranial injury
In a CT model additional indicators were the presence of
petechial haemorrhages, obliterationof the third ventricleor
basal cisterns, subarachnoid bleeding, mid-line shift, and
non-evacuated haematoma
The strength of predictors of outcomes varies according to
whether patients are from high or low-middle income
countries
These prognosticmodels, that include simple variables, are
available on the internet (www.crash2.lshtm.ac.uk/)
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impact on the management and outcomes of patients
with traumatic brain injury.
CRASH trial collaborators by country (number of patients randomised)
Albania (41 patients): Fatos Olldashi (national coordinator), Itan Muzha
(Central Military University Hospital National Trauma Centre, 35); Nikolin
Filipi ( University Hospital “Mother Teresa” Tirana, 6).
Argentina (359 patients): Roberto Lede, Pablo Copertari, Carolina
Traverso, Alejandro Copertari (IAMBE—national and regional
coordinators for southern Latin America); Enrique Alfredo Vergara,
Carolina Montenegro, Roberto Ruiz de Huidobro, Pantaleón Saladino
(Hospital San Bernardo, 106); Karina Surt, José Cialzeta, Silvio Lazzeri
(Hospital Escuela Jose de San Martin, 52); Gustavo Piñero, Fabiana Ciccioli
(Hospital Municipal “Dr Leonidas Lucero,” 37); Walter Videtta, María
Fernanda Barboza (Hospital Dr Ramón Carrillo, 35); Silvana Svampa,
Victor Sciuto (Hospital Castro Rendon, 28); Gustavo Domeniconi, Marcelo
Bustamante (Hospital Zonal General De Agudos “Heroes de Malvinas,”
27); Maximiliano Waschbusch (Policlinico Sofia T de Santamarina. 20);
María Paula Gullo (Hospital Municipal Dr Hector J D’Agnillo, 17); Daniel
Alberto Drago (Hospital Nacional Profesor Alejandro Posadas, 11); Juan
Carlos Arjona Linares (Hospital Español de Mendoza, 10); Luis Camputaro
(Hospital Italiano, 10); Gustavo Tróccoli (Hospital “Dr José Penna,” 5);
Hernán Galimberti (Hospital Aleman, 1).
Australia (13 patients): Mandy Tallott (Gold Coast Hospital, 13).
Austria (21 patients): Christian Eybner, Walter Buchinger
(Waldviertelklinikum Standort Horn, 17); Sylvia Fitzal (Wilhelminenspital
der Stadt Wien, 4).
Belgium (403 patients): Guy Mazairac (national coordinator), Véronique
Oleffe, Thierry Grollinger, Philippe Delvaux, Laurent Carlier (Centre
Hospitalier Regional de Namur, 356); Veronique Braet (AZ Klina Hospital,
34); Jean-Marie Jacques (Hospital of Jolimont, 11); Danielle de Knoop
(Clinique Saint-Luc, 2).
Brazil (119 patients): Luiz Nasi (national coordinator), Humberto Kukhuyn
Choi, Mara Schmitt (Hospital de Pronto Socorro de Porto Alegre, 113);
André Gentil (Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo, 5); Flavio Nacul (Clínica São Vicente, 1).
Chile (3 patients): Pedro Bedoya Barrios (Hospital Regional Copiapo, 3).
China (87 patients): Chen Xinkang, Lin Shao Hua, Huang Han Tian
(Zhongshan City People’s Hospital, 79); Cai Xiaodong (Sheng Zheng
Second People’s Hospital, 8).
Colombia (832 patients): Wilson Gualteros, Alvaro Ardila Otero (Hospital
Universitario San Jorge, 216); Miguel Arango (national coordinator,
regional coordinator for northern Latin America and Caribbean), Juan Ciro,
Hector Jaramillo (Gloria GarciaClinica Las Americas, 199); Ignacio
Gonzalez, Carolina Gomez (Hospital General de Medellin, 119); Arturo
Arias, Marco Fonseca, Carlos Mora (Hospital Erasmo Meoz, 90); Edgar
Giovanni Luna Cabrera, José Luis Betancurth, Porfirio Muñoz (Hospital
Departamental de Nariño, 51); Jesus Alberto Quiñónez, Maria Esther
Gonzalez Castillo (Hospital San Andres, 37); Orlando Lopez (Hospital
Federico Lleras, 31); Rafael Perez Yepes, Diana Leon Cuellar, Gerson Paez
(Hospital El Tunal, 24); Hernán Delgado Chaves, Pablo Emilio Ordoñez
(Hospital Civil de Ipiales, 21); Ricardo Plata, Martha Pineda (Hospital
Universitario del Valle, 15); Libardo Enrique Pulido (Hospital Regional de
Duitama, 12); John Sergio Velez Jaramillo (Hospital Timothy Britton, 12);
Carlos Rebolledo (Organización Clinica General del Norte, 5).
Costa Rica (20 patients): Oscar Palma (Hospital México, 20).
Cuba (404 patients): Caridad Soler (national coordinator); Irene Pastrana,
Raul Falero (Hospital Abel Santamaria Cuadrado, 77); Mario Domínguez
Perera, Agustín Arocha García, Raydel Oliva (Hospital Universitario
“Arnaldo Milián Castro,” 55); Hubiel López Delgado (Hospital Provincial
Docente “Manuel Ascunce Domenech,” 43); Aida Madrazo Carnero, Boris
Leyva López (Hospital VI Lenin, 42); Angel Lacerda Gallardo, Amarilys
Ortega Morales (Hospital General de Morón, 40); Humberto Lezcano
(Hospital General Universitario “Carlos Manuel de Cèspedes,” 38);
Marcos Iraola Ferrer (Hospital Universitario “Dr Gustavo Aldereguia Lima,”
37); Irene Zamalea Bess, Gladys Rivas Canino (Hospital Miguel Enriquez,
36); Ernesto Miguel Piferrer Ruiz (Hospital Clínico-Quirúrgico Docente
“Saturnino Lora,” 32); Orlando Garcia Cruz (Centro de Investigaciones
Médico-Quirúrgicas, 4).
Czech Republic (961 patients): Petr Svoboda (national coordinator), Ilona
Kantorová, Jirˇl´ Ochmann, Peter Scheer, Ladislav Kozumplík, Jitka Marsˇová
(Research Institute for Special Surgery and Trauma, 852); Karel Edelmann
(Masaryk Hospital, 41); Ivan Chytra, Roman Bosman (Charles University
Hospital, Plzen, 35); Hana Andrejsová (University Hospital Hradec
Kralove, 15); Jan Pachl (Hospital Kralovske Vinohgrady, 9); Jan Bürger
(Hospital Pribram, 7); Filip Kramar (Univerzity Karlovy Neurochirurgicka
Klinika, 2).
Ecuador (258 patients): Mario Izurieta Ulloa (national coordinator), Luis
Gonzalez, Alberto Daccach, Antonio Ortega, Stenio Cevallos (Hospital Luis
Vernaza, 202); Boris Zurita Cueva (Hospital de la Policia Guayaquil, 16);
Marcelo Ochoa (Hospital Jose Carrasco Arteaga, 11); Jaime Velásquez
Tapia (Hospital Naval, 11); Jimmy Hurtado (Clínica Central, 8); Miguel
Chung Sang Wong (Hospital Militar de Guayaquil, 5); Roberto Santos
(Hospital Regional del IESS “Dr Teodoro Maldonado Carbo,” 5).
Egypt (775 patients): Hussein Khamis (national coordinator), Abdul Hamid
Abaza, Abdalla Fekry, Salah El Kordy, Tarek Shawky (Mataria Teaching
Hospital, 364); Hesham El-Sayed (national coordinator), Nabil Khalil,
Nader Negm, Salem Fisal (Suez Canal University, 180); Mamdouh Alamin,
Hany Shokry (Aswan Teaching Hospital, 160); Ahmed Yahia Elhusseny,
Atif Radwan, Magdi Rashid (Zagazig University Hospital, 71).
Georgia (56 patients): Tamar Gogichaisvili (national coordinator), George
Ingorokva, Nikoloz Gongadze (Neurosurgery Department of Tbilisi State
Medical University, 55); Alexander Otarashvili (Tbilisi 4th Hospital, 1).
Germany (27 patients): Waltraud Kleist (Ernst Moritz Arndt University, 14);
Mathias Kalkum (Kreiskrankenhaus Tirschenreuth, 8); Peter Ulrich
(Klinikum Offenbach, 5).
Ghana (7 patients): Nii Andrews (Narh-Bita Hospital, 7).
Greece (20 patients): George Nakos (University Hospital of Ioannina, 8);
Antonios Karavelis (University General Hospital of Larissa, 5); George
Archontakis (Chania General Hospital “St George,” 4); Pavlos Myrianthefs
(KAT Hospital of Athens, 3).
India (973 patients): Yadram Yadav, Sharda Yadav, R Khatri, Arvind Baghel
(NSCB Medical College, 177); Mazhar Husain (national coordinator for
north India), Deepak Jha (King George Medical College, 105); Wu Hoong
Chhang, Manohar Dhandhania, Choden Fonning (North Bengal Neuro
Research Centre, 65); S N Iyengar, Sanjay Gupta (G R Medical College, 51);
R R Ravi, K S Bopiah, Ajay Herur (Medical Trust Hospital Kochi, 51); N K
Venkataramana (national coordinator for south India), A Satish (Manipal
Hospital, 50); K Bhavadasan, RaymondMorris, Ramesh S (Medical College
Hospital Trivandrum, 50); A Satish (Abhaya Hospital, 42); Yashbir Dewan,
Yashpal Singh (Christian Medical College, 36); Rajesh Bhagchandani,
Sanjana Bhagchandani (Apex Hospital Bhopal, 32); Vijaya Ushanath
Sethurayar (Meenakshi Mission Hospital and Research Centre, 32); Sojan
Ipe, G Sreekumar (MOSC Medical College Hospital, 32); Manas Panigrahi,
Agasti Reddy (Nizam’s Institute of Medical Sciences, 28); Varinder Khosla,
Sunil Gupta (Postgraduate Institute of Medical Education and Research,
28); Haroon Pillay, Nisha Thomas (Baby Memorial Hospital, 25);
Krishnamurthy Sridhar, Bobby Jose (V H S Hospital, 22); Nadakkavvkakan
Kurian (JubileeMission Hospital, 20); Shanti Praharaj, Shibu Pillai (National
Institute of Mental Health and Neurosciences, 17); Ramana (Care Hospital
(16); Sanjay Gupta, Smita Gupta (Sri Sai Hospital, 16); Dilip Kiyawat (Hirabi
Cowasji Jehangir Medical Research Institute, 15); Kishor Maheshwari
(Maheshwari Orthopaedic Hospital, 13); Dilip Panikar (Amrita Institute of
Medical Sciences, 11); Jayant Chawla (Hartej Maternity and Nursing Home,
7); Satyanarayana Shenoy, Annaswamy Raja (Kasturba Medical College
and Hospital, 7); Yeshomati Rupayana (Choitram Hospital and Research
Centre, 6); Suryanarayan Reddy (Gowri Gopal Superspeciality Hospital,
6); Nelanuthala Mohan (Apex Hospital Visakhapatnam, 3); Shailesh Kelkar
(Central India Institute of Medical Sciences, 3); Yadram Yadav (Marble City
Hospital and Research Centre, 3); Jayant Chawla (Government Medical
College Amritsar, 1); Mukesh Johri (Johri Hospital, 1); Yadram Yadav
(National Hospital Jabalpur, 1).
Indonesia (238 patients): Nyoman Golden (national coordinator), Sri
Maliawan (Sanglah General Hospital, 222); Achmad Fauzi, Umar Farouk
(Sidoarjo General Hospital, 14).
Iran (233 patients): Esmaeel Fakharian, Amir Aramesh (Naghavi University
Hospital, 110); Maasoumeh Eghtedari, Farhad Ahmadzadeh, Alireza
Gholami (Fatemeh Zahra Hospital, 85); Maasoumeh Eghtedari, Farhad
Ahmadzadeh (Social Security Hospital, 38).
Ireland (113 patients): Patrick Plunkett, Catherine Redican, Geraldine
McMahon (St James’s Hospital, 113).
Italy (9 patients): Maria Giuseppina Annetta (Università Cattolica del
Sacro Cuore, 4); Homère Mouchaty (Università di Firenze, 3); Eros
Bruzzone (Ospedale San Martino, 2).
Ivory Coast (3 patients): Béatrice Harding (CHU de Cocody, 3).
Kenya (2 patients): Mahmood Qureshi (Aga Khan Hospital, 2).
Malaysia (176 patients): Zamzuri Idris, Jafri Abdullah NC, Ghazaime
Ghazali, Abdul Rahman Izaini Ghani (Hospital University Science Malaysia,
162); Fadzli Cheah (Ipoh Specialist Hospital, 14).
Mexico (17 patients): Alfredo Cabrera (national coordinator); José Luis
Mejía González (Hospital General Regional No 1, 12); José Luis Mejía
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González (Hospital General de Queretaro, 4); Jorge Loría-Castellanos
(Hospital General Regional No 25, 1).
New Zealand (43 patients): Suzanne Jackson, Robyn Hutchinson (Dunedin
Hospital, 43).
Nigeria (180 patients): Edward Komolafe (national coordinator),
Augustine Adeolu, Morenikeji Komolafe (Obafemi Awolowo University
Teaching Hospitals, 77); Olusanya Adeyemi-Doro, Femi Bankole (Lagos
University Teaching Hospital, 43); Bello Shehu, Victoria Danlami (Usmanu
Danfodiyo University Teaching Hospital, 36); Olugbenga Odebode
(University of Ilorin Teaching Hospital, 15); Kehinde Oluwadiya (Lautech
Teaching Hospital, 7); Ahmed Sanni (Lagos State University Teaching
Hospital, 1); Herb Giebel (Seventh Day Adventist Hospital, 1); Sushil Kumar
(St Stephen’s Hospital, 1).
Pakistan (17 patients): Rashid Jooma (Jinnah Postgraduate Medical Centre,
17).
Panama (7 patients): Jose Edmundo Mezquita (Complejo Hospitalario M
A Guerrero, 7).
Paraguay (10 patients): Carlos Ortiz Ovelar (Instituto de Prevision Social,
10).
Peru (8 patients): Marco Gonzales Portillo (Hospital Nacional “Dos de
Mayo,” 6); Diana Rodriguez (national coordinator) (Hospital Nacional
Arzobispo Loayza, 2).
Romania (319 patients): Laura Balica (national coordinator), Bogdan
Oprita, Mircea Sklerniacof, Luiza Steflea, Laura Bandut (Spitalul Clinic de
Urgenötùa Bucuresö ti, 282); Adam Danil, Remus Iliescu (Sfantum
Pantelimon Hospital, 28); Jean Ciurea (Prof Dr D Bagdasar Clinical
Emergency Hospital, 9).
Saudi Arabia (32 patients): Abdelazeem El-Dawlatly, Sherif Alwatidy (King
Khalid University Hospital, 24); Walid Al-Yafi, Megahid El-Dawlatly (King
Khalid National Guard Hospital, 8).
Serbia (23 patients): Ranka Krunic-Protic, Vesna Janosevic (Klinicki Centar
Srbije, 23).
Singapore (23 patients): James Tan (national coordinator) (National
Neuroscience Institute, 21); Charles Seah (Changi General Hospital, 2).
Slovakia (179 patients): Sˇtefan Trenkler (national coordinator), Matusˇ
Humenansky, Tatiana Stajancˇová (Reiman Hospital, 71); Ivan Schwendt,
Anton Laincz (NsP Poprad, 39); Zeman Julius, Stano Maros (Nemocnica
Bojnice, 25); Jozef Firment (FNsp Kosice, 12); Maria Cifranicˇova (Ns
P Trebisov, 11); Beata Sániová (Faculty Hospital in Martin, 10); Karol Kalig
(NsP Ruzinov, 4); Sonˇa Medekova (NsP Nové Zámky, 3); Radovan Wiszt
(NsP LiptovskyMikulas, 2); NsP F D Roosevelt, 1); IvanMacˇuga (NsP Zilina,
1).
South Africa (366 patients): Bennie Hartzenberg (national coordinator),
Grant du Plessis, Zelda Houlie (Tygerberg Academic Hospital, 307);
Narendra Nathoo, Sipho Khumalo (Wentworth Hospital, 57); Ralph Tracey
(Curamed Kloof Hospital, 1).
Spain (259 patients): Angeles Muñoz-Sánchez (national coordinator),
Francisco Murillo-Cabezas NC, Juan Flores-Cordero, Dolores Rincón-
Ferrari (Hospital Universitario Virgen del Rocio, 133); Martin Rubi, Lopez
Caler (Hospital Torrecárdenas, 37); Maite Misis del Campo, Luisa Bordejé
Laguna (Hospital Universitario Germans Trias i Pujol, 32); Juan Manuel
Nava (Hospital Mútua de Terrassa, 20); Miguel Arruego Minguillón
(Hospital Universitario de Girona Dr Josep Trueta, 12); Alfonso Muñoz
Lopez (Hospital Carlos Haya, 10); Luis Ramos-Gómez (Hospital General
de La Palma, 6); Victoria de la Torre-Prados (Hospital Universitario Virgen
de la Victoria, 5); Romero Pellejero (Hospital General Yagüe, 4).
Sri Lanka (132 patients): Véronique Laloë (national coordinator), Bernhard
Mandrella, Suganthan (Batticaloa General Hospital-Médecins Sans
Frontières, 84); Sunil Perera (National Hospital of Sri Lanka, 39);
Véronique Laloë, Kanapathipillai Mahendran (Point-Pedro Base Hospital,
9).
Switzerland (160 patients): Reto Stocker (national coordinator), Silke
Ludwig (national coordinator) (University Hospital of Zurich, 133); Heinz
Zimmermann (University Hospital Bern, 15); Urs Denzler (Kantonsspital
Schaffhausen, 12).
Thailand (579 patients): Surakrant Yutthakasemsunt (national
coordinator), Warawut Kittiwattanagul, Parnumas Piyavechvirat, Pojana
Tapsai, Ajchara Namuang-jan (Khon Kaen Regional Hospital, 535); Upapat
Chantapimpa (Chiangrai Prachanuko Hospital, 12); Chanothai Watanachai,
Pusit Subsompon (Rayong Hospital, 11); Wipurat Pussanakawatin, Pensri
Khunjan (Krabi Hospital, 10); Sakchai Tangchitvittaya, Somsak Nilapong
(Suratthani Hospital, 8); Tanagorn Klangsang, Wibul Taechakosol (Roi Et
Hospital, 2); Atirat Srinat (Lampang Hospital, 1).
Tunisia (63 patients): Zouheir Jerbi (national coordinator), Nebiha Borsali-
Falfoul, Monia Rezgui (Hospital Habib Thameur, 63).
Turkey (2 patients): Nahit Cakar (Istanbul Medical Faculty, 2).
Uganda (43 patients): Hussein Ssenyonjo, Olive Kobusingye (Makerere
Medical School, 43).
UK (1391 patients): Gabrielle Lomas, David Yates, Fiona Lecky (Hope
Hospital, 209); Anthony Bleetman, Alan Baldwin, Emma Jenkinson, Shiela
Pantrini (Birmingham Heartlands Hospital, 123); James Stewart, Nasreen
Contractor, Trudy Roberts, Jim Butler (North Manchester General Hospital,
85); Alan Pinto, Diane Lee (Royal Albert Edward Infirmary, 83); Nigel
Brayley, Karly Robbshaw, Clare Dix (Colchester General Hospital, 79);
Sarah Graham, Sue Pye (Whiston Hospital, 69); Marcus Green, Annie
Kellins (Selly Oak Hospital, 61); Chris Moulton, Barbara Fogg (Royal Bolton
Hospital, 51); Rowland Cottingham, Sam Funnell, Utham Shanker
(Eastbourne District General Hospital, 50); Claire Summers, Louise Malek
(Trafford General Hospital, 41); Rowland Cottingham (national
coordinator), Christopher Ashcroft, Jacky Powell (Royal Sussex County
Hospital, 38); Steve Moore, Stephanie Buckley (Countess of Chester
Hospital, 36); Mandy Grocutt, Steve Chambers (Worthing Hospital, 34);
Amanda Morrice, Helen Marshall (Medway Maritime Hospital, 29); Julia
Harris, Wendy Matthews, Jane Tippet (Chelsea and Westminster Hospital,
28); Simon Mardell, Fiona MacMillan, Anita Shaw (Furness General
Hospital, 27); Pramod Luthra, Gill Dixon (Royal Oldham Hospital, 26);
Mohammed Ahmed, John Butler, Mike Young (Stepping Hill Hospital, 26);
Sue Mason, Ian Loveday (Northern General Hospital, 25); Christine Clark,
Sam Taylor (Blackburn Royal Infirmary, 23); Paul Wilson (Cheltenham
General Hospital, 23); Kassim Ali, Stuart Greenwood (Fairfield General
Hospital, 23); Martin White, Rosa Perez (Queen Elizabeth the Queen
Mother Hospital, 21); Sam Eljamel (Ninewells Hospital andMedical School,
19); Jonathan Wasserberg, Helen Shale (Queen Elizabeth Hospital
Birmingham, 18); Colin Read, John McCarron (Russell’s Hall Hospital, 18);
Aaron Pennell (Princess Alexandra Hospital, 16); Gautam Ray (Princess
Royal Hospital, 14); John Thurston, Emma Brown (Darent Valley Hospital,
13); Lawrence Jaffey, Michael Graves (Royal Liverpool University Hospital,
12); Richard Bailey, Nancy Loveridge (Chesterfield and North Derbyshire
Royal Hospital, 10); Geraint Evans, Shirleen Hughes, Major Kafeel Ahmed
(Withybush General Hospital, 10); Jeremy Richardson, Claire Gallagher
(Aberdeen Royal Infirmary, 8); Titus Odedun, Karen Lees (Ormskirk and
District General Hospital, 8); David Foley, Nick Payne (Queen Mary’s
Hospital, 8); Alan Pennycook, Carl Griffiths (Arrowe Park Hospital, 6);
David Moore, Denise Byrne (City Hospital Birmingham, 5); Sunil Dasan (St
Helier Hospital, 4); Ashis Banerjee, Steve McGuinness (Whittington
Hospital, 4); Claude Chikhani (Doncaster Royal Infirmary, 2); Nigel Zoltie,
Ian Barlow (Leeds General Infirmary, 2); Ian Stell (Bromley Hospital, 1);
William Hulse, Jacqueline Crossley (Harrogate District Hospital, 1);
LaurenceWatkins (Institute of Neurology, 1); Balu Dorani (Queen Elizabeth
Hospital Gateshead, 1).
Vietnam (2 patients)—Truong Van Viet (Cho Ray Hospital, 2).
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